PC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchOpenEvidence raised $200 million in a financing round reported on October 20, 2025, at an approximately $6 billion private-market valuation. The clinician-focused medical AI company’s valuation had risen from $3.5 billion only about three months earlier. However, that figure is now historical: OpenEvidence subsequently announced a $250 million Series D at a $12 billion valuation in January 2026.
The deal highlights investor enthusiasm for specialized AI applications—but a private financing valuation is not the same as cash in the bank, a public-company market capitalization, profitability, or proof that the product improves patient outcomes.
As an Amazon Associate I earn from qualifying purchases.
What happened in the OpenEvidence financing?
According to TechCrunch, citing The New York Times, OpenEvidence raised $200 million in October 2025 at a valuation of approximately $6 billion. Fierce Healthcare reported that the round was a Series C and that OpenEvidence’s chief executive confirmed the financing and valuation.
Free tools Windows power users keep installed
One-click scans. No signup required.
The round was reportedly led by GV, formerly Google Ventures, with participation from Sequoia Capital, Kleiner Perkins, Blackstone, Thrive Capital, Coatue Management, BOND, and Craft.
#1 Best Overall
The October transaction was a private-company financing. The $6 billion figure represented the valuation assigned during that round; it was not a sale price, public stock-market value, or amount raised. The company raised $200 million, while investors priced the company at about $6 billion.
The available reporting attributes the October financing to secondary coverage and the company’s CEO rather than a directly accessible official OpenEvidence announcement. Deal details should therefore be understood as reported and attributed, rather than as terms independently verified through a public filing.
How quickly did OpenEvidence’s valuation rise?
OpenEvidence’s reported valuation increased sharply in 2025:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
| Date | Reported financing | Valuation |
|---|---|---|
| February 2025 | Series A | $1 billion |
| July 2025 | $210 million Series B | $3.5 billion |
| October 2025 | $200 million Series C | About $6 billion |
| January 2026 | $250 million Series D | $12 billion |
Using the reported figures, the valuation rose from $3.5 billion in July to $6 billion in October—an increase of approximately 71% in roughly three months. In January 2026, OpenEvidence announced a further $250 million financing at a $12 billion valuation, roughly doubling the October figure.
These are financing-round valuations, not guaranteed returns for investors. A valuation can rise because investors expect future growth, but it does not establish that the company is profitable, that its shares could immediately be sold for that price, or that its technology has been clinically validated.
What does OpenEvidence do?
OpenEvidence is marketed as a medical search and AI platform for verified healthcare professionals. It is designed to retrieve and synthesize medical evidence, provide rapid answers, and cite medical literature and clinical sources.
Rank #2
The “ChatGPT for doctors” label is useful shorthand, but it is incomplete. OpenEvidence is better described as a specialized evidence-retrieval and clinical decision-support assistant—not a general-purpose chatbot and not an autonomous physician.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →The company has described licensed and strategic content relationships involving sources including the New England Journal of Medicine and JAMA Network. Its July 2025 announcement also described DeepConsult, an agent intended to analyze and cross-reference large numbers of peer-reviewed studies.
A specialized platform may have advantages over a general-purpose AI system: a more focused medical corpus, clinician-oriented workflows, citations, and potentially clearer source provenance. But citations do not guarantee that an answer is correct or that the cited study supports the conclusion. Performance can vary by specialty, question, patient context, and the quality or currency of the underlying evidence.
Who can use OpenEvidence?
OpenEvidence has primarily marketed its core product to verified U.S. physicians, nurses, and other healthcare professionals. TechCrunch reported that access was free for verified medical professionals and supported by advertising.
Free access for eligible clinicians does not mean unrestricted public access. Verification requirements, availability, and commercial terms may change. The product is not intended to replace a physician’s judgment, an institutional protocol, specialist consultation, or review of primary literature.
For patients and general consumers, an AI-generated answer—even one accompanied by citations—should not be treated as medical advice or used to make diagnosis or treatment decisions.
How many people use it?
Reported usage grew rapidly, although the figures are not directly interchangeable:
- TechCrunch reported about 15 million clinical consultations per month around October 2025.
- Fierce Healthcare reported more than 16 million monthly clinical consultations around the same period.
- OpenEvidence later said it supported approximately 18 million consultations from verified U.S. doctors and healthcare professionals in December 2025, according to TechCrunch.
- In its July 2025 announcement, the company claimed that more than 40% of U.S. physicians logged in daily.
“Consultations,” “searches,” “questions,” “sessions,” and “users” describe different measures. The 40% figure is a company claim, not an independently established government statistic. Usage demonstrates engagement, not improved diagnosis, treatment, safety, or patient outcomes.
How does OpenEvidence make money?
The reported model was free access for verified clinicians, funded primarily through advertising to healthcare and life-sciences companies. That creates a potentially valuable audience: medical professionals who influence or make high-value clinical decisions.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsOpenEvidence acquired Amaro in September 2025 to strengthen its advertising infrastructure. The company described the acquisition as a way to expand its AI-native advertising capabilities.
It also partnered with Veeva on Open Vista, a project aimed at clinical-trial access, drug discovery, and helping users understand or adopt approved medicines. That points to possible expansion beyond point-of-care search into pharmaceutical, medical-affairs, clinical-trial, and enterprise workflows.
The advertising questions matter
An ad-supported clinical information product faces a trust challenge. Healthcare organizations and clinicians need to know:
- How sponsored content is labeled and separated from evidence synthesis.
- Whether commercial messages can influence rankings, summaries, recommendations, or search results.
- How advertising is targeted and reviewed for compliance.
- Whether clinicians can distinguish a model-generated answer from promotional material.
- What controls exist for pharmaceutical and medical-device advertising at the point of care.
The available financing coverage establishes the free, ad-supported model, but it does not establish all of those safeguards or explain the company’s revenue mix. Investors therefore need to distinguish a large clinician audience from proven advertising revenue, enterprise contracts, or durable margins.
Why did investors back OpenEvidence?
The investment case appears to rest on several possibilities:
- A concentrated professional audience: Verified clinicians may be commercially valuable to healthcare and life-sciences advertisers.
- Frequent workflow use: If clinicians repeatedly use a tool to find evidence, it may become embedded in their routines.
- Specialized content: Licensed medical sources and editorial or evidence relationships may be harder to reproduce than a generic chatbot interface.
- Expansion opportunities: Health-system software, medical education, pharmaceutical information, clinical trials, and medical affairs could provide additional revenue streams.
- AI market positioning: A focused clinical product may be easier to sell to healthcare professionals than a general-purpose system with no specialized workflow.
These are strategic interpretations, not proof that OpenEvidence has achieved profitability, clinical superiority, or a durable competitive moat. The valuation assumes that adoption can be converted into trustworthy and scalable monetization.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.OpenEvidence versus general-purpose AI
A specialized medical AI system and a general-purpose chatbot involve different trade-offs.
| Specialized clinical AI may offer | General-purpose AI may offer |
|---|---|
| Focused medical sources and terminology | Broader knowledge and flexible general assistance |
| Citations and source-oriented retrieval | Wide availability across tasks and platforms |
| Clinician-specific workflows | Rapid model development and broad consumer adoption |
| Potentially clearer provenance | Often lower barriers to experimentation |
Neither category is automatically safe or accurate. OpenEvidence can still hallucinate, misread a study, apply evidence to the wrong patient, omit relevant information, or express too much certainty. Proprietary systems may also be difficult for independent researchers to audit.
Quick wins for a faster PC:
Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Clear out junk files and repair common Windows errorsFree Scan →There is no basis in the supplied reporting to say that OpenEvidence is categorically more accurate than ChatGPT or another model. A meaningful comparison would require an independent evaluation that disclosed its clinical questions, specialties, sample size, scoring method, comparison models, citation accuracy, and safety outcomes.
Best Value
What the valuation assumes—and what could go wrong
For investors, the central question is whether the company’s rapid repricing reflects durable economics or enthusiasm around a fast-growing AI category. Key assumptions include:
- Clinician usage will continue after the novelty of generative AI fades.
- Free usage can be converted into advertising, enterprise, or workflow revenue without damaging trust.
- Licensed content and clinical distribution will remain defensible as major AI companies enter healthcare.
- Inference, research-agent, and content-licensing costs can be controlled.
- Health systems and life-sciences companies will adopt the product despite long procurement, security, and compliance processes.
Risks include competition from general-purpose AI companies, EHR vendors, established clinical reference services, and traditional point-of-care tools. Clinical software also faces privacy, malpractice, regulatory, governance, and liability concerns. A product can be popular with individual clinicians while still requiring extensive validation before a health system permits patient-specific use.
What clinicians and health systems should evaluate
Clinicians considering OpenEvidence should check whether answers provide relevant and current citations, whether the underlying sources can be inspected, and how the system handles conflicting guidelines, contraindications, dosage questions, rare diseases, and patient-specific complexity. They should also review data retention, privacy, institutional approval, and employer policy.
Health systems should additionally examine authentication, EHR integration, audit logs, security controls, data-use restrictions, administrative settings, vendor liability, indemnification, clinician training, and independent validation on their own patient populations. An ad-supported model may be unacceptable in some clinical environments even if the product is available at no direct cost.
For investors and analysts, the most important unanswered commercial questions include the split between advertising and enterprise revenue, the cost of licensed content and model inference, advertising safeguards, retention, conversion from usage to revenue, and the durability of the company’s content and workflow advantages.
Timeline
- Early 2020s: OpenEvidence was founded; published accounts differ on whether the inception was in 2021 or 2022.
- February 19, 2025: The company announced a Sequoia-led Series A at a $1 billion valuation.
- July 15, 2025: OpenEvidence announced a $210 million Series B at a $3.5 billion valuation.
- September 10, 2025: It announced the acquisition of Amaro.
- October 16, 2025: OpenEvidence and Veeva announced the Open Vista partnership.
- October 20, 2025: The $200 million financing at an approximately $6 billion valuation was reported.
- January 21, 2026: OpenEvidence announced a $250 million Series D at a $12 billion valuation.
For the company’s published announcements, see the OpenEvidence press-release archive.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
